Trials / Withdrawn
WithdrawnNCT00728533
Open-Label, Randomised Parallel-Group Study
The Rationale of the Study is to Demonstrate That Degarelix Given at Three-month Dosing Intervals Will Produce and Maintain Androgen Deprivation in Prostate Cancer Patients Through Immediate and Prolonged Testosterone Suppression, and to Provide Confirmatory Evidence of the Safety of Degarelix.
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Ablation Therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Degarelix | Prostate Cancer - Degarelix powder and solvent for suspension for injection. Three-month depot in two dosing regimens. |
| DRUG | Degarelix | Prostate Cancer - Degarelix powder and solvent for suspension for injection. Three-month depot in two dosing regimens. |
Timeline
- First posted
- 2008-08-06
- Last updated
- 2011-03-18
Source: ClinicalTrials.gov record NCT00728533. Inclusion in this directory is not an endorsement.